Ceftriaxone
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Ceftriaxone
- Pharmacist Assessment Report
- Ceftriaxone: Third-generation cephalosporin antibiotic → polyclonal hyperviscosity syndrome
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ceftriaxone: Third-generation cephalosporin antibiotic → polyclonal hyperviscosity syndrome
One-Sentence Summary
Ceftriaxone is an injectable cephalosporin antibiotic that is already marketed in Canada. The TxGNN model predicts it may be relevant to polyclonal hyperviscosity syndrome, with a score of 0.9939. The data compiled for this report contain no clinical trials and no publications on this prediction, so the evidence is model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | polyclonal hyperviscosity syndrome |
| TxGNN Prediction Score | 0.9939 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 13 of 13) |
| Number of DINs | 13 (marketed: 13) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for ceftriaxone are not available in the data compiled for this report. Ceftriaxone is a bactericidal beta-lactam antibiotic that kills bacteria by interfering with cell-wall synthesis.
Polyclonal hyperviscosity syndrome is a different kind of problem. It is a rheologic disorder in which high levels of immunoglobulins or other proteins make the blood abnormally thick. It is not an infection, and an antibacterial would not be expected to act on the cause.
We found no plausible mechanistic link between the drug and this condition. The high TxGNN score comes from network-based pattern matching and has no clinical or literature support. It should be read as a hypothesis-generating signal only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Ceftriaxone is marketed in Canada as a single-ingredient injectable product. All licences on record are valid, and none are cancelled. The licence table is generated separately by the site program.
Safety Considerations
- Drug Interactions (100 interactions were found in total; the main ones are listed below):
- Major: calcium-containing products (calcium chloride, calcium gluconate, calcium glucoheptonate).
- Moderate: aminoglycosides (kanamycin, neomycin, streptomycin) and picosulfuric acid.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or publications, and no credible mechanism links an antibacterial to a protein-driven hyperviscosity disorder. At Evidence Level L5, the risks of exposing patients to an antibiotic with no expected benefit outweigh any potential value.
To proceed, the following is needed:
- A plausible mechanistic hypothesis, supported by preclinical or laboratory data
- Any published case-level or observational data on ceftriaxone in this condition
- Detailed mechanism-of-action data for ceftriaxone
- Package insert warnings and contraindications from Health Canada, for a safety review
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.